COA THERAPEUTICS

CoA Therapeutics was founded in 2018 with the aim of developing novel therapies for difficult to treat and rare genetic disorders by harnessing advances in understanding of the CoA pathway... CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the Coenzyme A synthetic pathway. While PanK2 is inactivated in PKAN patients, other isoforms known as PanK1 and PanK3 are still active. This leads to decreased PanK activity and impaired CoA synthesis. Conversely, in organic acidurias, build-up of metabolic intermediates can inhibit the activity of all three isoforms of PanK and impair CoA synthesis. CoA Therapeutics' small molecules can bind to all three PanK isoforms - although in PKAN, PanK2 is defective - prevent feedback inhibition, and thereby increase PanK activity and increase CoA synthesis... CoA Therapeutics' approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski,..

Primary location: San Francisco United States